Stay updated on Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial page.

Latest updates to the Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange Detected- Removed version v3.1.0 and added notice about government funding lapse and current NIH Clinical Center status with links, plus new version tag v3.2.0. Overall, the page now communicates current operating status and a newer version rather than the old one.SummaryDifference2%
- Check21 days agoChange DetectedMinor capitalization updates for disease names and a version bump from v3.0.2 to v3.1.0. No substantive changes to core content or availability.SummaryDifference0.2%
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page updates from Revision: v3.0.1 to v3.0.2, and the Back to Top link has been removed; overall, there are no significant changes to core content, pricing, stock, or time slots.SummaryDifference0.1%
- Check42 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%
- Check50 days agoChange DetectedThe web page has undergone significant updates, including the addition of new lymphoma types and treatment options, while removing several previously listed lymphoma types and related topics. The facility name and location have also been updated.SummaryDifference5%
- Check57 days agoChange DetectedThere are no significant changes to the web page content.SummaryDifference0.6%
Stay in the know with updates to Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial page.